The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.

The top executives of Moderna, Akamai, and FMC just bought stock on the open market. All three shares are in the red for 2025 ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...

Last night, two purchases of Moderna’s stock by a firm controlled by MRNA CEO Stephane Bancel were reported. Bancel’s company, called Boston Biotech Ventures, bought 102,821 shares for an ...

Moderna shares experienced a significant surge in trading on Thursday, posting a 5.58% gain in European markets and an impressive jump of up to 16% on the NASDAQ. This remarkable performance was ...

Mergers and acquisitions grabbed the spotlight in the biotech sector this week after Jazz Pharmaceuticals JAZZ announced an agreement to acquire Chimerix CMRX. Meanwhile, other pipeline and regulatory ...